LILRB4/CD85k/ILT3, His & Avi, Human
LILRB4/CD85k/ILT3, His & Avi, Human

Immobilized LILRB4/CD85k/ILT3, His & Avi, Human, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-LILRB4 Antibody, hFc Tag with the EC50 of 2.6ng/ml determined by ELISA.

LILRB4/CD85k/ILT3, His & Avi, Human

The purity of LILRB4/CD85k/ILT3, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

LILRB4/CD85k/ILT3, His & Avi, Human

LILRB4/CD85k/ILT3, His & Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.

LILRB4/CD85k/ILT3, His & Avi, Human

LILRB4,also known as CD85k and LIR-5, ILT-3, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT-3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.
Z05602
¥69,021.00

Ask us a question
Product Introduction
Species Human
Protein Construction
LILRB4/CD85k/ILT3 (Gln22-His257)_x000D_
Accession # AAH26309		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 28.6 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 38-42 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • LILRB4/CD85k/ILT3, His & Avi, Human
    • LILRB4/CD85k/ILT3, His & Avi, Human

    Immobilized LILRB4/CD85k/ILT3, His & Avi, Human, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-LILRB4 Antibody, hFc Tag with the EC50 of 2.6ng/ml determined by ELISA.

  • LILRB4/CD85k/ILT3, His & Avi, Human
    • LILRB4/CD85k/ILT3, His & Avi, Human

    The purity of LILRB4/CD85k/ILT3, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • LILRB4/CD85k/ILT3, His & Avi, Human
    • LILRB4/CD85k/ILT3, His & Avi, Human

    LILRB4/CD85k/ILT3, His & Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.


Background
Target Background LILRB4,also known as CD85k and LIR-5, ILT-3, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT-3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.
Synonyms HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.